Grant: Operating Grant
McGill University
$386,196.00
Polymeric membrane lactobacillus formulation for use in type II diabetes.
FY 2008-09
Summary
Recent changes in human diet and lifestyle have resulted in a dramatic increase in number of diabetics worldwide. The continuous use of currently available synthetic drugs has associated limitations. This proposal is an attempt to address the urgent need to develop a safe, natural and economical strategy to treat or prevent the emerging global epidemic of type 2 diabetes. A novel oral artificial cell microcapsule formulation incorporating live feruloyl esterase active probiotic bacterial cells has been developed. We have obtained very encouraging preliminary results indicating the potential of this formulation in type 2 diabetes. Here, we propose to investigate the feasibility, suitability, mode of action and pre-clinical efficacy of this formulation in an experimental animal model. If successful, this formulation will be used to treat and/or prevent type 2 diabetes. In addition, this study will be a step towards exploiting the important potential of non-pathogenic FAE active bacterial cells for future clinical applications.
Department
Program
Operating Grant
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
172053
Name
Prakash Satya
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Polymeric membrane lactobacillus formulation for use in type II diabetes.
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$386,196
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Diabetes Mellitus; Feruloyl Esterase; Microcpsule; Polymeric Membrane
Abstract
Recent changes in human diet and lifestyle have resulted in a dramatic increase in number of diabetics worldwide. The continuous use of currently available synthetic drugs has associated limitations. This proposal is an attempt to address the urgent need to develop a safe, natural and economical strategy to treat or prevent the emerging global epidemic of type 2 diabetes. A novel oral artificial cell microcapsule formulation incorporating live feruloyl esterase active probiotic bacterial cells has been developed. We have obtained very encouraging preliminary results indicating the potential of this formulation in type 2 diabetes. Here, we propose to investigate the feasibility, suitability, mode of action and pre-clinical efficacy of this formulation in an experimental animal model. If successful, this formulation will be used to treat and/or prevent type 2 diabetes. In addition, this study will be a step towards exploiting the important potential of non-pathogenic FAE active bacterial cells for future clinical applications.
Competitiondate
200809
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Prakash, Satya
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $386,196~ $0~
